Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ashizawa, Masahiro  [Clear All Filters]
2024
Nagayama T, Fujiwara S-I, Tominaga R, Yokoyama D, Noguchi A, Furuki S, Oyama T, Koyama S, Murahashi R, Nakashima H, et al. Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2024:1-7.
Oyama T, Fujiwara S-I, Tominaga R, Yokoyama D, Noguchi A, Furuki S, Koyama S, Murahashi R, Nakashima H, Hyodo K, et al. Effects of CD34 cell dose on engraftment and long-term outcomes after allogeneic bone marrow transplantation. Clin Transplant. 2024;38(4):e15313.
2023
Nagayama T, Fujiwara S-I, Tominaga R, Yokoyama D, Noguchi A, Furuki S, Oyama T, Koyama S, Murahashi R, Nakashima H, et al. Early reversal of the lymphocyte-to-monocyte ratio after allogeneic-hematopoietic stem cell transplantation is associated with reduced relapse and improved prognosis. Clin Transplant. 2023:e15116.
Tamaki M, Akahoshi Y, Ashizawa M, Misaki Y, Koi S, Kim S-W, Ozawa Y, Fujiwara S-I, Kako S, Matsuoka K-I, et al. Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023;13(1):7166.
2021
Minakata D, Fujiwara S-I, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi S-I, Toda Y, Ito S, Nagayama T, et al. Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis. Leuk Res. 2021;112:106750.
2019
Ashizawa M, Akahoshi Y, Nakano H, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, Tamaki M, et al. Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. Biol Blood Marrow Transplant. 2019.
2016
Nakano H, Ashizawa M, Akahoshi Y, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Sato M, et al. Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding. Int J Hematol. 2016.